- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00840255
Brief Behavioral Treatment of Insomnia in Military Veterans: Phase 2 (BBTIMVII) (BBTIMVII)
15 de junho de 2012 atualizado por: Anne Germain, University of Pittsburgh
Treatment of Insomnia in Military Veterans:Phase 2
The purpose of this study is to adapt and test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), finalizing a treatment manual.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
Insomnia is one of the most common reasons for referral to mental health services in active duty personnel.
Chronic insomnia often persists post-deployment, contributes to poor mental and physical health outcomes, and requires targeted interventions.
Effective behavioral treatments of insomnia have not been adapted and tested for the treatment of chronic insomnia comorbid to combat-related mental disorders and stress reactions.
In addition, effective behavioral insomnia treatments are typically delivered over an 8-week period.
This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help.
The goal is to adapt and test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
We call this intervention the Brief Behavioral Treatment of Insomnia for Military Veterans (BBTI-MV).
The proposed study includes two phases.
The specific aims of Phase II are: (1) To explore the effects of BBTI-MV on sleep and daytime symptoms of psychiatric distress.
We anticipate that participants randomized to BBTI-MV will show a higher categorical response rate and remission for sleep symptoms than subjects randomized to IC. (2) To evaluate in a preliminary manner the durability of therapeutic gains and by conducting a naturalistic follow-up assessment six months post-treatment in responders.
(3) To explore whether the nature of combat-related experiences, time since deployment and since, return to the US, deployment theater, medication use and change in dosage, mood and anxiety or disorders affect sleep treatment adherence and outcomes.
Tipo de estudo
Intervencional
Inscrição (Real)
40
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15237
- Western Psychiatric Institute & Clinic
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Age is 18 years old and older
- Military returnees from OIF/OEF
Meet diagnostic criteria for chronic insomnia as defined by:
a. Complaint of sleep latency >30 minutes, or wake time after sleep onset >30 minutes, or Sleep Efficiency <85%, or a complaint of non-restorative sleep
- Frequency of insomnia complaint >3 times per week;
- Duration of insomnia complaint >1 month
- Associated with at least one daytime consequences
- If using sleep medications, medication and dosage have not been changed in the past month, and will remain unchanged for the duration of the acute treatment phase of the study (i.e., 4 weeks)
- If using other psychotropic medications, medication and dosage have not been changed in the past 2 months, and will remain unchanged for the duration of the acute treatment phase of the study (i.e., 4 weeks)
Exclusion Criteria:
- Active duty personnel, or reservists/national guards scheduled to re-deploy if their departure date is < 2 months from the consent date
- Untreated, current, and severe PTSD as determined on the SCID.
- Untreated, current, and severe Major Depressive Disorder as determined by the Structured Clinical Interview for DSM-IV and a score > 30 on the Beck Depression Inventory
- Psychotic or bipolar disorder
- Current substance or alcohol use disorder as determined by the SCID or by positive drug toxicology results
- Unstable medical condition
- Hospitalization in the previous 2 weeks for a medical condition or surgery for which recovery overlaps with the study onset and duration
- Seizure disorder or open skull brain injury.
- Current sleep disorders such as nightmare disorder, restless legs syndrome, or suspected sleep disorder requiring polysomnographic assessment, such as obstructive sleep apnea or periodic leg movements.
- Sleep apnea revealed during the screening sleep study.
- Pregnancy.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Breif Behavioral Treatment of Insomnia
Effective behavioral insomnia treatments are typically delivered over an 8-week period.
This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help.
The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
|
Twenty participants will be randomized to BBTI-MV.
As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic.
If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts.
The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes.
Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
|
|
Outro: Information Control
This arm of the study does not receive the Brief Behavioral Treatment for Insomnia.
This arm will act as the control arm.
|
Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia.
The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences.
No recommendations for altering sleep schedules will be made by the assigned therapist.
Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Pittsburgh Sleep Quality Index (PSQI)
Prazo: Baseline and Post Intervention
|
Baseline and Post Intervention
|
|
Pittsburgh Sleep Diary
Prazo: Weekly
|
Weekly
|
|
PSQI Addendum for PTSD (PSQIA)
Prazo: Baseline and Post
|
Baseline and Post
|
|
Sleep Quality defined by: PIRS-20 and ISI
Prazo: Screening,Baseline, and Post
|
Screening,Baseline, and Post
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
PTSD symptom severity as measured by the CAPS
Prazo: Screening
|
Screening
|
|
Post Sleep Self Report: PSEQ-SV and POST
Prazo: Screening
|
Screening
|
|
Depression: BDI
Prazo: Baseline and Post
|
Baseline and Post
|
|
Anxiety: BAI
Prazo: Baseline and Post
|
Baseline and Post
|
|
Medical History: MHQ, MEDHIST_2WK, MOS
Prazo: Screening, Baseline, and Post
|
Screening, Baseline, and Post
|
|
Trauma History: THQ,CES,PCL-C,ICG
Prazo: Screening, Baseline, and Post
|
Screening, Baseline, and Post
|
|
Sleepiness: EPWORTH, BASS
Prazo: Screening, Baseline, and Post
|
Screening, Baseline, and Post
|
|
Mood and Behavior: BIS/BAS, SMITH, PANAS
Prazo: Screening, Baseline, and Post
|
Screening, Baseline, and Post
|
|
Expectations and Satisfaction: TEQ-94, Client Satisfaction Survey
Prazo: Baseline and Post
|
Baseline and Post
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Anne Germain, PhD, University of Pittsburgh, Department of Psychiatry
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Links úteis
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de abril de 2009
Conclusão Primária (Real)
1 de abril de 2012
Conclusão do estudo (Real)
1 de abril de 2012
Datas de inscrição no estudo
Enviado pela primeira vez
9 de fevereiro de 2009
Enviado pela primeira vez que atendeu aos critérios de CQ
9 de fevereiro de 2009
Primeira postagem (Estimativa)
10 de fevereiro de 2009
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
18 de junho de 2012
Última atualização enviada que atendeu aos critérios de controle de qualidade
15 de junho de 2012
Última verificação
1 de junho de 2012
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PRO08070327
- NIMH: 1 R34 MH080696
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em BBTI-MV
-
Royal Marsden NHS Foundation TrustImperial College London; Institute of Cancer Research, United Kingdom; RM Partners...RecrutamentoFumar | Alcoolismo | Doenças Urológicas | Hipertensão | Diabetes | Câncer de próstata | Câncer de bexiga | Câncer Renal | Câncer Urológico | Problema de saúde mental | Câncer de testículoReino Unido
-
NHS Greater Glasgow and ClydeUniversity of GlasgowDesconhecido
-
University of PittsburghNational Institute of Mental Health (NIMH)ConcluídoInsônia CrônicaEstados Unidos
-
University of Alabama, TuscaloosaUniversity of Alabama at Birmingham; National Institute on Aging (NIA); NIH Office...Ainda não está recrutandoInsônia | HIV | Envelhecimento | ConhecimentoEstados Unidos
-
Rutgers, The State University of New JerseyConcluídoDepressão | Transtorno do Espectro Autista | Autismo | Transtorno do Espectro Autista com Linguagem Funcional PrejudicadaEstados Unidos
-
University of MiamiNational Institute of Nursing Research (NINR)Recrutamento
-
Themis Bioscience GmbHWalter Reed Army Institute of Research (WRAIR)ConcluídoChikungunyaPorto Rico
-
Bandim Health ProjectAarhus University Hospital; Rigshospitalet, DenmarkConcluídoMortalidade | Hospitalização | Eventos adversosGuiné-Bissau
-
Themis Bioscience GmbHConcluídoInfecção pelo Vírus ChikungunyaReino Unido
-
IRCCS Centro Neurolesi "Bonino-Pulejo"Concluído